Level Biotechnology Inc. (3118.TWO)
TWD 32.0
(0.0%)
TWD 32.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 70.21 Million | 65.07 Million | 155.95 Million | 83.22 Million | 109.78 Million |
| Net Income | 78.65 Million | 73.15 Million | 84.89 Million | 72.54 Million | 47.39 Million |
| Depreciation & Amortization | 19.72 Million | 19.5 Million | 19.79 Million | 20.82 Million | 20.32 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -14.56 Million | -9.11 Million | 66.48 Million | 2.74 Million | 38.05 Million |
| Other non-cash items | -4.84 Million | -2.12 Million | -1.28 Million | -1.55 Million | 3.99 Million |
| Investing Cash Flow | -10.89 Million | -10.18 Million | -8.78 Million | -2.63 Million | -2.9 Million |
| Investments in PPE | -7.66 Million | -6.73 Million | -9.15 Million | -2.54 Million | -2.42 Million |
| Acquisitions | 229 Thousand | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | -1.65 Million | 370 Thousand | -565 Thousand | -1.55 Million | - |
| Other Investing Activities | -1.8 Million | -3.97 Million | 932 Thousand | -380 Thousand | - |
| Financing Cash Flow | -55.4 Million | -64.34 Million | -54.52 Million | -44.69 Million | -35.23 Million |
| Debt repayment | -70 Thousand | - | - | - | -758 Thousand |
| Dividends payments | -55.17 Million | -61.66 Million | -51.92 Million | -42.18 Million | -32.45 Million |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | 2.88 Million | - | 56 Thousand | 44 Thousand | -2.02 Million |
| Accounts receivables | 7.6 Million | - | - | - | 7.63 Million |
| Accounts payables | -14.79 Million | - | - | - | 27.19 Million |
| Inventory | -15.38 Million | -17.52 Million | 7.36 Million | 13.09 Million | -6 Million |
| Other working capital | -6.78 Million | - | - | - | 9.22 Million |
| Cash at beginning of period | 463.49 Million | 472.95 Million | 380.31 Million | 344.41 Million | 272.77 Million |
| Cash at end of period | 467.4 Million | 463.49 Million | 472.95 Million | 380.31 Million | 344.41 Million |
| Capital Expenditure | -7.66 Million | -6.73 Million | -9.15 Million | -2.54 Million | -2.42 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 3.91 Million | -9.45 Million | 92.63 Million | 35.89 Million | 71.64 Million |
| Free Cash Flow | 62.54 Million | 58.33 Million | 146.79 Million | 80.68 Million | 107.35 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 14.04 Million | 23.95 Million | 78.65 Million | 25.14 Million | 14.25 Million | 18.74 Million |
| Depreciation & Amortization | 5.3 Million | 5.26 Million | 19.72 Million | 5.15 Million | 4.92 Million | 4.87 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -13.36 Million | -37.46 Million | -14.56 Million | 15 Million | 7.38 Million | -16.81 Million |
| Other non-cash items | -1.93 Million | -1.19 Million | -4.84 Million | -1.39 Million | -1.19 Million | -1.32 Million |
| Investing Cash Flow | -1.32 Million | 7.6 Million | -10.89 Million | -7.96 Million | 1.27 Million | -562 Thousand |
| Investments in PPE | -520 Thousand | -635 Thousand | -7.66 Million | -943 Thousand | -2.38 Million | -2.37 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | -550 Thousand | 6.02 Million | -1.65 Million | -6.2 Million | 4.75 Million | 200 Thousand |
| Other Investing Activities | -250 Thousand | 2.2 Million | -1.8 Million | -814 Thousand | -1.1 Million | 1.38 Million |
| Financing Cash Flow | -4.03 Million | -1.09 Million | -55.4 Million | 1.92 Million | -55.95 Million | -688 Thousand |
| Debt repayment | -83 Thousand | - | - | - | - | - |
| Dividends payments | - | - | -55.17 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -4.03 Million | - | 2.88 Million | 2.88 Million | - | - |
| Accounts receivables | -12.52 Million | - | - | - | - | - |
| Accounts payables | -11.93 Million | - | - | - | - | - |
| Inventory | 9.23 Million | -7.28 Million | -15.38 Million | 3.35 Million | 302 Thousand | -3.34 Million |
| Other working capital | 1.77 Million | - | - | - | - | - |
| Cash at beginning of period | 465.39 Million | 467.4 Million | 463.49 Million | 427.91 Million | 463.38 Million | 464.33 Million |
| Cash at end of period | 457.65 Million | 465.39 Million | 467.4 Million | 467.4 Million | 427.91 Million | 463.38 Million |
| Capital Expenditure | -520 Thousand | -635 Thousand | -7.66 Million | -943 Thousand | -2.38 Million | -2.37 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -7.74 Million | -2 Million | 3.91 Million | 39.49 Million | -35.46 Million | -959 Thousand |
| Free Cash Flow | -2.91 Million | -9.15 Million | 62.54 Million | 44.58 Million | 16.83 Million | -2.08 Million |
PCLO
MRCC
CBBI
8210
RUIS
2180